Quick Answer
KYNTRA BIO, INC. reported Cash and Equivalents of $47.87 million for fiscal year 2025.
KYNTRA BIO, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $47.87M | -5.2% |
| 2024 | $50.48M | -38.1% |
| 2023 | $81.55M | -47.6% |
| 2022 | $155.70M | -9.1% |
| 2021 | $171.22M | -74.8% |
| 2020 | $678.39M | +437.3% |
| 2019 | $126.27M | +41.5% |
| 2018 | $89.26M | -86.8% |
| 2017 | $673.66M | +287.6% |
| 2016 | $173.78M | +13.3% |
| 2015 | $153.32M | -7.3% |
| 2014 | $165.46M | +116.8% |
| 2013 | $76.33M | +96.4% |
| 2012 | $38.87M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $117.97M | -9.9% | +404.9% |
| June 30, 2025 | $23.37M | -83.4% | -30.5% |
| March 31, 2025 | $33.61M | -68.2% | -33.4% |
| December 31, 2024 | $50.48M | -55.6% | -61.5% |
| September 30, 2024 | $131.00M | +8.3% | -6.9% |
| June 30, 2024 | $140.71M | -7.8% | +33.1% |
| March 31, 2024 | $105.73M | -43.9% | -7.0% |
| December 31, 2023 | $113.69M | -27.0% | -6.0% |
- KYNTRA BIO, INC. showed a decrease of -5.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2012–2025 period, KYNTRA BIO, INC.’s cash and equivalents has grown by 23.2% (from $38.87 million to $47.87 million).
- The most recent figure is from KYNTRA BIO, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: